Literature DB >> 18469033

Regional grey matter atrophy in clinically isolated syndromes at presentation.

R G Henry1, M Shieh, D T Okuda, A Evangelista, M L Gorno-Tempini, D Pelletier.   

Abstract

BACKGROUND: The presence and degree of neuronal degeneration already existing in patients at their initial presentation with a clinically isolated syndrome suggestive of multiple sclerosis (CIS) is unclear, and whole brain or whole normalised grey matter analyses have not demonstrated significant atrophy in CIS cohorts at clinical presentation. Voxel-based analyses allow detection of regional atrophy throughout the brain and, therefore, may be sensitive to regional atrophy in CIS patients, and these changes may correspond with clinical disability.
METHODS: This study used a modified voxel-based morphometry (VBM) method to correct for lesion effects to analyse regional atrophy and perform voxel-wise correlations between volume and clinical metrics in 41 untreated CIS patients at presentation compared with 49 healthy controls.
RESULTS: The results confirmed that there was no significant difference in whole normalised grey matter volume between CIS and controls, whereas VBM showed significant areas of bilateral thalamic, hypothalamic, putamen and caudate atrophy. Voxel-wise correlations with clinical measures showed that cerebellar volumes correlated with clinical cerebellar function, nine-hole peg test scores and the Multiple Sclerosis Functional Composite (MSFC) score, and that the MSFC score was also correlated with putamen volume. Lastly, T1 lesion volumes were found to correlate with thalamic and hippocampal atrophy, suggesting a link between white matter lesions and grey matter degeneration at the earliest stages of multiple sclerosis.
CONCLUSIONS: Atrophy is present in CIS patients at presentations, particularly in the thalamus, and other deep grey matter structures. Furthermore, the correlations with clinical metrics suggest the importance of this atrophy to clinical status and the correlation with T1 lesion load suggests a possible role of Wallerian degeneration.

Entities:  

Mesh:

Year:  2008        PMID: 18469033      PMCID: PMC4827711          DOI: 10.1136/jnnp.2007.134825

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  37 in total

1.  Thalamic neurodegeneration in multiple sclerosis.

Authors:  Alberto Cifelli; Marzena Arridge; Peter Jezzard; Margaret M Esiri; Jacqueline Palace; Paul M Matthews
Journal:  Ann Neurol       Date:  2002-11       Impact factor: 10.422

2.  A voxel-based morphometric study of ageing in 465 normal adult human brains.

Authors:  C D Good; I S Johnsrude; J Ashburner; R N Henson; K J Friston; R S Frackowiak
Journal:  Neuroimage       Date:  2001-07       Impact factor: 6.556

3.  Dissociating perceptual and conceptual implicit memory in multiple sclerosis patients.

Authors:  Diana Blum; Andrew P Yonelinas; Tracy Luks; David Newitt; Joonmi Oh; Ying Lu; Sarah Nelson; Donald Goodkin; Daniel Pelletier
Journal:  Brain Cogn       Date:  2002-10       Impact factor: 2.310

4.  Hypothalamic lesions in multiple sclerosis.

Authors:  I Huitinga; C J De Groot; P Van der Valk; W Kamphorst; F J Tilders; D F Swaab
Journal:  J Neuropathol Exp Neurol       Date:  2001-12       Impact factor: 3.685

5.  Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study.

Authors:  Andrew J Fabiano; Jitendra Sharma; Bianca Weinstock-Guttman; Frederick E Munschauer; Ralph H Benedict; Robert Zivadinov; Rohit Bakshi
Journal:  J Neuroimaging       Date:  2003-10       Impact factor: 2.486

6.  MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis.

Authors:  Jeroen J G Geurts; Ilona E W Reuling; Hugo Vrenken; Bernard M J Uitdehaag; Chris H Polman; Jonas A Castelijns; Frederik Barkhof; Petra J W Pouwels
Journal:  Magn Reson Med       Date:  2006-03       Impact factor: 4.668

7.  Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS.

Authors:  A Traboulsee; J Dehmeshki; P A Brex; C M Dalton; D Chard; G J Barker; G T Plant; D H Miller
Journal:  Neurology       Date:  2002-07-09       Impact factor: 9.910

8.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.

Authors:  Catherine M Dalton; Declan T Chard; Gerard R Davies; Katherine A Miszkiel; Dan R Altmann; Kryshani Fernando; Gordon T Plant; Alan J Thompson; David H Miller
Journal:  Brain       Date:  2004-03-03       Impact factor: 13.501

9.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

Authors:  D T Chard; C M Griffin; G J M Parker; R Kapoor; A J Thompson; D H Miller
Journal:  Brain       Date:  2002-02       Impact factor: 13.501

10.  Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.

Authors:  M Wylezinska; A Cifelli; P Jezzard; J Palace; M Alecci; P M Matthews
Journal:  Neurology       Date:  2003-06-24       Impact factor: 9.910

View more
  79 in total

1.  Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study.

Authors:  Alvino Bisecco; Maria A Rocca; Elisabetta Pagani; Laura Mancini; Christian Enzinger; Antonio Gallo; Hugo Vrenken; Maria Laura Stromillo; Massimiliano Copetti; David L Thomas; Franz Fazekas; Gioacchino Tedeschi; Frederik Barkhof; Nicola De Stefano; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2015-04-14       Impact factor: 5.038

Review 2.  [Clinically isolated syndrome].

Authors:  M Platten; T Lanz; M Bendszus; R Diem
Journal:  Nervenarzt       Date:  2013-10       Impact factor: 1.214

Review 3.  MR imaging of gray matter involvement in multiple sclerosis: implications for understanding disease pathophysiology and monitoring treatment efficacy.

Authors:  Massimo Filippi; M A Rocca
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-31       Impact factor: 3.825

4.  Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome.

Authors:  Tomas Uher; Jana Blahova-Dusankova; Dana Horakova; Niels Bergsland; Michaela Tyblova; Ralph H B Benedict; Tomas Kalincik; Deepa P Ramasamy; Zdenek Seidl; Jesper Hagermeier; Manuela Vaneckova; Jan Krasensky; Eva Havrdova; Robert Zivadinov
Journal:  J Neurol       Date:  2014-06-22       Impact factor: 4.849

5.  Quantitative T2' imaging in patients with clinically isolated syndrome.

Authors:  L Y Reitz; M Inglese; J Fiehler; J Finsterbusch; B Holst; C Heesen; R Martin; S Schippling
Journal:  Acta Neurol Scand       Date:  2012-01-03       Impact factor: 3.209

6.  Early silent microstructural degeneration and atrophy of the thalamocortical network in multiple sclerosis.

Authors:  Michael Deppe; Julia Krämer; Jan-Gerd Tenberge; Jasmin Marinell; Wolfram Schwindt; Katja Deppe; Sergiu Groppa; Heinz Wiendl; Sven G Meuth
Journal:  Hum Brain Mapp       Date:  2016-02-27       Impact factor: 5.038

7.  Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis.

Authors:  Martijn D Steenwijk; Marita Daams; Petra J W Pouwels; Lisanne J Balk; Prejaas K Tewarie; Jeroen J G Geurts; Frederik Barkhof; Hugo Vrenken
Journal:  Hum Brain Mapp       Date:  2015-01-27       Impact factor: 5.038

8.  Genetic associations with brain cortical thickness in multiple sclerosis.

Authors:  T Matsushita; L Madireddy; T Sprenger; P Khankhanian; S Magon; Y Naegelin; E Caverzasi; R L P Lindberg; L Kappos; S L Hauser; J R Oksenberg; R Henry; D Pelletier; S E Baranzini
Journal:  Genes Brain Behav       Date:  2015-03-05       Impact factor: 3.449

Review 9.  Causes, effects and connectivity changes in MS-related cognitive decline.

Authors:  Carolina de Medeiros Rimkus; Martijn D Steenwijk; Frederik Barkhof
Journal:  Dement Neuropsychol       Date:  2016 Jan-Mar

10.  A voxel-based morphometry study of disease severity correlates in relapsing-- remitting multiple sclerosis.

Authors:  A Prinster; M Quarantelli; R Lanzillo; G Orefice; G Vacca; B Carotenuto; B Alfano; A Brunetti; V Brescia Morra; M Salvatore
Journal:  Mult Scler       Date:  2009-12-22       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.